Krupple-Like Factor 5 is a Potential Therapeutic Target and Prognostic Marker in Epithelial Ovarian Cancer

Area of Science:

• Oncology
• Molecular Biology
• Gynecologic Oncology

Background:

• Epithelial ovarian cancer (EOC) is a leading cause of cancer death among women.
• Current treatments for advanced EOC have limited efficacy, highlighting the need for novel therapeutic targets.
• Krupple-like factor 5 (KLF5), a transcription factor, is implicated in various cancers, but its role in EOC is not well-defined.

Purpose of the Study:

• To investigate the expression and function of KLF5 in epithelial ovarian cancer.
• To explore the relationship between KLF5 and the signal transducer and activator of transcription 3 (STAT3) signaling pathway in EOC.
• To evaluate KLF5 as a potential therapeutic target for EOC.

Main Methods:

• Immunohistochemical analysis of KLF5 protein expression in 425 primary EOC samples using tissue microarrays.
• Functional studies involving forced expression and knockdown of KLF5 in EOC cell lines (MDAH2774, OVISE, OVSAHO).
• Assessment of cell growth, migration, invasion, epithelial-to-mesenchymal transition (EMT), and spheroid self-renewal upon KLF5 manipulation. Evaluation of KLF5's effect on cisplatin-induced apoptosis and STAT3 signaling.

Main Results:

• KLF5 was overexpressed in 53% of EOC samples and correlated with aggressive tumor markers.
• Forced KLF5 expression increased cell growth in a low-expressing EOC cell line.
• KLF5 knockdown reduced cell growth, migration, invasion, EMT, and spheroid self-renewal in high-expressing EOC cell lines.
• Downregulation of KLF5 enhanced cisplatin-induced apoptosis and was linked to STAT3 pathway activation.

Conclusions:

• KLF5 plays a pro-tumorigenic role in epithelial ovarian cancer.
• KLF5 contributes to EOC progression by activating the STAT3 signaling pathway.
• KLF5 represents a promising molecular therapeutic target for epithelial ovarian cancer treatment.